Progressive Myoclonic Epilepsy Type 8 (PME8/EPM8, CERS1-Related): Comprehensive Research Report

1. Disease Information

Overview. Progressive Myoclonic Epilepsy Type 8 (PME8; also designated EPM8) is an ultra-rare, autosomal recessive neurodegenerative disorder belonging to the progressive myoclonic epilepsy (PME) disease group. It is caused by biallelic loss-of-function mutations in CERS1 (ceramide synthase 1), which impair biosynthesis of C18-ceramide, a key sphingolipid in neuronal membranes. Clinically it presents in childhood-to-adolescence with action myoclonus, generalized tonic-clonic (GTC) seizures, and slowly progressive cognitive decline, sometimes accompanied by prominent ataxia and other movement-disorder features (PMC6336183; GARD).

Key identifiers: | Resource | ID | |---|---| | OMIM (phenotype) | #616230 — EPILEPSY, PROGRESSIVE MYOCLONIC, 8; EPM8 | | OMIM (gene) | *606919 — CERAMIDE SYNTHASE 1; CERS1 | | MONDO | MONDO:0014545 | | Orphanet | ORPHA:424027 | | HGNC gene symbol | CERS1 (hgnc — formerly LASS1, UOG1, GDD1) |

(Sources: OMIM 616230, OMIM 606919, Orphanet 424027)

Synonyms: "Progressive myoclonic epilepsy due to ceramide synthase 1 deficiency," "CERS1-related progressive myoclonic epilepsy," "EPM8," "PME type 8 due to CERS1 deficiency" (GARD).

Evidence base: All currently reported PME8 information derives from a very small number of aggregated case series/case reports (not large cohorts or EHR-scale data) — a single consanguineous Algerian family (index description) plus at least one additional unrelated case with a distinct genotype/phenotype. This is a disease characterized almost entirely at the individual-patient/family level rather than through population registries.

2. Etiology

Primary cause — genetic. PME8 is caused by homozygous (or compound heterozygous) loss-of-function variants in CERS1 on chromosome 19p13, encoding ceramide synthase 1 — a transmembrane endoplasmic-reticulum enzyme that catalyzes biosynthesis of C18-(dihydro)ceramide from stearoyl-CoA and a sphingoid base (OMIM 616230; PMC6336183).

Risk factors: - Genetic: Biallelic CERS1 pathogenic variants are necessary and sufficient. Consanguinity is a major risk factor — the index-family report (autosomal-recessive, homozygous mutation) arose in a consanguineous Algerian kindred, and the second reported case also had consanguineous parents (mixed indigenous/Portuguese/Dutch ancestry) ("Impairment of ceramide synthesis causes a novel progressive myoclonus epilepsy," Vanni et al., Ann Neurol 2014; PMC6336183). - Environmental: None identified; no toxin, infectious, or lifestyle risk factor has been described for this monogenic disorder. - Protective factors: None specifically documented for CERS1-related disease; there is no described modifier-allele or dietary/environmental protective factor in the literature to date. - Gene-environment interaction: Not documented; disease penetrance/expressivity data are too sparse (only a handful of reported patients) to assess environmental modulation.

3. Phenotypes

PME8 phenotypes cluster into neurologic signs/symptoms, cognitive/behavioral features, and EEG/imaging (laboratory-type) abnormalities. Onset is reported between ages 1–16 years across the ~5–6 published cases.

Phenotype characteristics: - Onset: Childhood to adolescence, reported range 1–16 years, most commonly 5–16 years for seizure/myoclonus onset (PMC6336183; GARD). - Severity/progression: Uniformly progressive and severe — "all patients also develop severe and progressive cognitive impairment in late childhood or adolescence," with EEG showing "progressive slowing of background activity and epileptic abnormalities," and MRI showing "cerebellar and brainstem atrophy" (search synthesis of OMIM content). - Phenotypic heterogeneity: The 2019 case report explicitly notes phenotypic variability — a patient "phenotypically different from the others in literature due to prominent ataxia and other dyskinetic movement disorders in addition to myoclonus," distinguishing it from the four previously reported cases where ataxia was not a primary presenting feature (PMC6336183). - Quality of life impact: Not formally studied (no EQ-5D/SF-36 data identified); qualitatively, progressive dementia, refractory myoclonus, and motor decline severely impair independence and daily functioning based on case narratives (e.g., discontinuation of school/functional decline implied by progressive cognitive impairment and movement disorder).

4. Genetic/Molecular Information

Causal gene: CERS1 (OMIM 606919), chromosome 19p13 (search results variably cite 19p13.11/19p13.12 — confirm exact cytoband against Ensembl/NCBI Gene before final KB entry). CERS1 has 10 exons* producing multiple transcripts (alternative promoter usage/splicing) and up to five protein isoforms per gene-summary sources (GeneCards synthesis).

Reported pathogenic variants: 1. Founder/index family (Algerian, consanguineous): homozygous nonsynonymous missense mutation in CERS1 identified in 4 affected siblings, reducing ceramide synthase activity and C18-ceramide levels (Vanni et al., Ann Neurol 2014, PMID: 24782409). 2. Second unrelated family: novel homozygous missense variant p.Arg255Cys (genomic position cited as Chr19:18,990,187 in the source report) identified in a 22-year-old male with prominent ataxia; parents were heterozygous carriers (PMC6336183). 3. ClinVar-cataloged variants include: NM_021267.5(CERS1):c.419C>T (p.Pro140Leu) and c.717A>G (p.Ala239=) — both submitted in association with "Progressive myoclonic epilepsy type 8" (ClinVar RCV000700377; ClinVar RCV002108622).

Variant classification/type: Missense variants predominate among reported cases (as opposed to truncating/null alleles), consistent with hypomorphic rather than complete loss-of-function alleles, which may be necessary for postnatal viability given the severe phenotype of complete Cers1 loss in mouse models (see Mechanism, below).

Allele frequency: No population allele-frequency data (gnomAD/1000 Genomes/TOPMed) for the specific pathogenic alleles were retrievable via the searches performed in this session; given the rarity of the disease (prevalence <1/1,000,000) and consanguinity-linked ascertainment, pathogenic CERS1 alleles are expected to be essentially absent or present only as very rare heterozygous carriers in general population databases. This should be independently verified in gnomAD before curation rather than asserted from this report.

Somatic vs. germline: Exclusively germline (constitutional), autosomal recessive.

Functional consequences: Loss-of-function / hypomorphic — reduced CERS1 enzymatic activity, decreased C18-ceramide synthesis, and consequent ~50% reduction of total brain ceramide in the mouse ortholog model (see below). Cell-based (neuroblastoma) knockdown of CERS1 activates ER stress response and pro-apoptotic pathways (Vanni et al. 2014, synthesized from search results).

Modifier genes: None reported.

Epigenetics / chromosomal abnormalities: No epigenetic mechanism or chromosomal structural abnormality (translocation, CNV) has been reported for PME8; all described cases are point (missense) variants.

5. Environmental Information

No environmental factors, lifestyle factors, or infectious triggers have been documented as contributing to PME8 onset or severity — the disorder is monogenic. No exposure data are available in CTD, TOXNET, or similar databases specific to CERS1/PME8 based on this session's search.

6. Mechanism / Pathophysiology

Molecular pathway: CERS1 sits in the de novo sphingolipid biosynthesis pathway. It is a transmembrane ER enzyme that condenses stearoyl-CoA (an 18-carbon fatty acyl-CoA) with a sphingoid base (sphinganine/dihydrosphingosine) to generate C18-(dihydro)ceramide, the direct precursor of C18-ceramide and downstream complex sphingolipids (sphingomyelins, glycosphingolipids) (PMC6336183; GeneCards/Reactome synthesis). CERS1 is the most highly expressed ceramide synthase isoform in CNS neurons, particularly in neocortex, hippocampus, and cerebellum (Purkinje cells) (Vanni et al. 2014 synthesis).

Causal chain (upstream → downstream): 1. Molecular: Biallelic CERS1 loss-of-function variant → reduced ceramide synthase 1 enzymatic activity 2. Biochemical: Decreased C18-(dihydro)ceramide synthesis → ~50% reduction in total brain ceramide (region-specific, most pronounced in cerebellum/brainstem) in the mouse ortholog model 3. Cellular: Sphingolipid membrane dyshomeostasis → ER stress response activation and pro-apoptotic signaling in neurons (shown by CERS1 knockdown in neuroblastoma cells); accumulation of intraneuronal autofluorescent lipofuscin and ubiquitylated protein aggregates, indicating impaired proteostasis/organelle homeostasis, especially in brainstem and cerebellum 4. Tissue: Progressive cerebellar Purkinje cell degeneration with dendritic abnormalities, and glial changes; cerebellar and brainstem (pontine) atrophy on MRI 5. Organism: Progressive myoclonic epilepsy phenotype — action myoclonus, GTC seizures, ataxia, dysarthria, progressive cognitive decline/dementia

Molecular/cellular process citations: The mouse model paper states that loss of Cers1 "leads to accumulation of lipofuscin ... associated with ubiquitylated proteins in many regions of the brain, suggesting that ceramide biosynthesis is critical for protein and organelle homeostasis" (Zhao et al., PLoS Genetics 2011, PMID: 21625621, synthesized). Neuroblastoma-cell CERS1 knockdown data indicate "activation of ER stress response and induction of proapoptotic pathways" (Vanni et al. 2014 synthesis).

Suggested ontology terms: - GO (biological process): ceramide biosynthetic process (GO:0046513); sphingolipid metabolic process (GO:0006665); ER stress response / unfolded protein response (GO:0034976); neuron apoptotic process (GO:0051402); Purkinje cell degeneration-adjacent GO terms as appropriate - GO (molecular function): ceramide synthase activity / sphingosine N-acyltransferase activity (relevant EC 2.3.1.24 catalytic activity) - GO (cellular component): endoplasmic reticulum membrane (GO:0005789) - CL (cell types): Purkinje cell (CL:0000121); cerebellar granule cell (secondary involvement plausible but not directly documented) - UBERON: cerebellum (UBERON:0002037); pons/brainstem (UBERON:0002037 is cerebellum — brainstem is UBERON:0002298; pons specifically UBERON:0000988); cerebral cortex/hippocampus (secondary, per neuronal expression pattern) - CHEBI: ceramide (CHEBI:17761); C18-ceramide (specific structural CHEBI term should be verified); sphinganine (CHEBI:16410); stearoyl-CoA (CHEBI:57288)

Note on differential mechanism vs. related genes: CERS2 (a paralog, chromosome 1q21) causes a phenotypically similar but molecularly distinct PME — CERS2 haploinsufficiency (heterozygous deletion) reduces very-long-chain (C24–C26) ceramides rather than C18-ceramide, with myoclonus, seizures, ataxia, and photosensitivity ("Reduced ceramide synthase 2 activity causes progressive myoclonic epilepsy," PMC4212479, synthesized). This is a distinct gene/disease and must not be conflated with CERS1/PME8 — the two are complementary but non-identical sphingolipid-synthesis PMEs (analogous to a deregulated_cellular_energetics-style paralog-substitution pattern, should this ever warrant a shared dismech module).

7. Anatomical Structures Affected

• Organ level: Primary — central nervous system (cerebral cortex, cerebellum, brainstem/pons). Secondary — none well documented (no reported cardiac, hepatic, renal, or other systemic organ involvement in the literature reviewed); labs in the ataxia-predominant case were explicitly normal for hematologic indices and liver/kidney function (PMC6336183).
• Body systems: Nervous system exclusively (per literature to date); no cardiovascular, respiratory, digestive, or endocrine involvement reported.
• Tissue/cell level: Cerebellar Purkinje cells (degeneration, dendritic abnormality — established robustly in the mouse ortholog model); cortical/hippocampal neurons (implicated via CERS1's neuronal expression pattern, though direct human histopathology has not been reported since no human autopsy/biopsy data were identified in this search).
• Subcellular level: Endoplasmic reticulum (site of CERS1 catalytic activity and ER-stress pathophysiology); secondary lysosomal/autophagic involvement is plausible given lipofuscin/ubiquitinated-protein accumulation but not formally characterized as a distinct organelle-level lesion.
• Localization/lateralization: Bilateral, symmetric involvement (cerebellar atrophy, brainstem/pontine atrophy) — no lateralized findings reported.

Suggested UBERON terms: cerebellum (UBERON:0002037), pons (UBERON:0000988), brainstem (UBERON:0002298), cerebral cortex (UBERON:0000956).

8. Temporal Development

• Onset: Childhood to adolescence. Across the small case series, ataxia can be the earliest sign (noted as early as age 1 in one case), with seizure/myoclonus onset most commonly between ages 5 and 16. Onset pattern is insidious/progressive rather than acute.
• Progression: Uniformly progressive and neurodegenerative — no static or self-limited course has been reported. Disease stages are not formally defined (no published staging system), but the natural history described is: early motor/ataxic signs → seizure onset → progressive myoclonus refractory to escalating antiseizure therapy → progressive cognitive decline/dementia → progressive imaging atrophy (cerebellar, brainstem).
• Rate of progression: "Slowly progressive" per multiple sources (e.g., "slowly progressive, moderate to severe cognitive impairment" — GARD/Orphanet synthesis), occurring over years (childhood/adolescent onset with continued decline into young adulthood, as the 22-year-old case at presentation illustrates).
• Remission: No spontaneous or treatment-induced remission has been reported; seizures may become controlled pharmacologically while myoclonus and cognitive decline continue to progress (as explicitly noted in the ataxia-predominant case: "controlled seizures but progressive cognitive decline and myoclonus worsening" under levetiracetam/primidone/clonazepam).
• Critical periods: Not formally studied; disease is fully genetic (present from conception), so there is no known window for primary prevention — only for early recognition/genetic counseling.

9. Inheritance and Population

• Prevalence: <1 per 1,000,000 (Orphanet-derived estimate, per search synthesis) — among the rarest of the PME subtypes.
• Incidence: Not separately reported (data insufficient given the extremely small number of published cases — a single index family plus isolated additional case reports).
• Inheritance pattern: Autosomal recessive.
• Penetrance: Reported as complete/high in the described homozygous cases (all homozygotes in the index family were symptomatic), though formal penetrance estimates are not available given the tiny case count.
• Expressivity: Variable — the ataxia-predominant case is explicitly noted as phenotypically distinct from the index-family cases (prominent ataxia/choreoathetosis vs. myoclonus/dementia-predominant presentation), indicating variable expressivity possibly genotype-dependent (different missense alleles).
• Genetic anticipation: Not reported/not applicable (missense variants, not a repeat-expansion disorder).
• Germline mosaicism: Not reported.
• Founder effects: The index family represents a consanguineous Algerian founder pedigree; whether the specific variant represents a population founder allele in North African populations has not been formally studied but is plausible given the consanguinity and geographic/ethnic clustering.
• Consanguinity: A major factor in both reported families — the index Algerian family and the second reported family (parents consanguineous, mixed indigenous/Portuguese/Dutch ancestry) both involved consanguineous unions, consistent with autosomal recessive ultra-rare disease ascertainment.
• Carrier frequency: Not established; presumed extremely low or unknown at the population level given rarity.
• Affected populations/geographic distribution: Documented cases: (1) Algerian-origin consanguineous family (Vanni et al. 2014); (2) a family of mixed indigenous, Portuguese, and Dutch ancestry (PMC6336183, likely South American/Brazilian ascertainment given the ancestry description, though the exact country was not confirmed in this search and should be verified against the primary source before curation). No broader geographic/ethnic prevalence data exist.
• Sex ratio: Insufficient data — both sexes have been reported affected (the ataxia-predominant case was male; sex distribution within the index sibship was not fully detailed in the search results and should be checked against the primary Vanni et al. 2014 paper).
• Age distribution: Pediatric/adolescent onset with survival into young adulthood documented (oldest reported patient age 22 at presentation).

10. Diagnostics

• Genetic testing (primary diagnostic modality): Given the rarity and phenotypic overlap with other PMEs, exome sequencing or a PME/epilepsy gene panel (including CERS1 alongside CSTB, EPM2A, NHLRC1, KCTD7, GOSR2, SCARB2, KCNC1, PRICKLE1, mitochondrial MT-TK, and NEU1) is the recommended diagnostic approach once syndromic/biochemical screening for the more common PMEs (Lafora, Unverricht-Lundborg, NCL, sialidosis, MERRF) is unrevealing. Single-gene CERS1 sequencing is reasonable when phenotype and/or consanguinity strongly suggest this specific etiology.
• EEG: Generalized epileptiform activity with progressive slowing of background activity; in at least one case, epileptiform discharges were not triggered by photic stimulation (distinguishing from some other PMEs where photosensitivity is prominent, e.g., CERS2-PME) (PMC6336183).
• Neuroimaging (MRI): Cerebellar atrophy and brainstem (particularly pontine) atrophy, progressive over the disease course.
• Laboratory/biochemical tests: No specific validated biomarker or enzymatic assay for clinical diagnosis is established; research-level assessment can include cellular/functional ceramide-synthase activity assays (as performed in the original research reports) but this is not a standard clinical diagnostic test. Routine labs (CBC, liver/renal function) are typically normal, helping exclude storage/metabolic mimics.
• Ancillary testing performed in reported cases to exclude mimics: Ophthalmologic exam (normal — helps exclude retinal/visual involvement seen in some NCLs/sialidosis); genetic testing negative for Friedreich's ataxia and spinocerebellar ataxias (SCA1, 2, 3, 6, 7, 12, 17) and DRPLA (PMC6336183).
• Differential diagnosis: The major PME differential includes Unverricht-Lundborg disease (CSTB), Lafora disease (EPM2A/NHLRC1), neuronal ceroid lipofuscinoses (NCL), sialidosis type I (NEU1), MERRF (mitochondrial MT-TK), Gaucher disease type 3, KCTD7-related PME (EPM3), GOSR2-related PME (EPM6/North Sea PME), SCARB2-related action myoclonus-renal failure syndrome (EPM4), and KCNC1-related myoclonus epilepsy and ataxia (EPM7/MEAK). Distinguishing features: Lafora shows early cognitive deterioration with prominent visual seizures and EEG background slowing; Unverricht-Lundborg preserves cognition longer with vertex spikes in REM sleep; CERS1-PME8 is distinguished by its consanguinity/AR pattern, ceramide-pathway biochemistry, and (in at least one case) prominent early ataxia/choreoathetosis alongside myoclonus.
• Screening: No population or newborn screening program exists for this ultra-rare disorder; diagnosis is reactive (symptom-triggered) with subsequent genetic counseling for consanguineous families with an affected proband (25% recurrence risk for future pregnancies).

11. Outcome/Prognosis

• Survival/mortality: No formal survival statistics are available given the extremely small reported cohort; the disease is understood to be progressive and neurodegenerative but is not reported as acutely fatal in childhood — the oldest reported patient was alive at 22 years with ongoing disease progression.
• Morbidity/function: Progressive functional decline is the rule — worsening myoclonus, cognitive impairment/dementia, ataxia, and dysarthria over years, despite pharmacologic seizure control. No formal disability or QOL instrument data (EQ-5D, SF-36) were identified.
• Complications: Refractory action myoclonus; progressive dementia; gait/motor disability from ataxia and dyskinetic movement disorder features (choreoathetosis, dystonic posturing).
• Recovery potential: None described — the disorder is neurodegenerative with no reported spontaneous improvement; therapy (antiseizure medications) controls seizures but does not halt cognitive or myoclonic progression.
• Prognostic factors: Insufficient data to identify formal prognostic biomarkers or predictors of disease course given the very small number of published cases; genotype (specific missense variant) may plausibly modify phenotype severity/expressivity (ataxia-predominant vs. myoclonus/dementia-predominant), but this is speculative pending more cases.

12. Treatment

No disease-modifying or curative therapy exists. Management is purely symptomatic/antiseizure, and reported experience is limited to the handful of published cases.

• Pharmacotherapy (antiseizure drugs trialed in reported cases):
• Valproic acid — used initially in one patient, later discontinued (NCIT:C740 or NCIT:C1467/Pharmacotherapy generic term; specific agent: CHEBI valproic acid)
• Topiramate (200 mg/day)
• Clonazepam (4 mg/day, later part of maintenance regimen)
• Primidone (200 mg/day, later part of maintenance regimen)
• Piracetam (1600 mg/day) — used for myoclonus, per the general PME anti-myoclonic pharmacology pattern
• Levetiracetam — part of the current/maintenance regimen in the reported case, achieving seizure control (PMC6336183)
• Class-wide PME literature (not CERS1-specific but broadly applicable) also highlights perampanel (a selective AMPA-receptor antagonist) as having demonstrated anti-myoclonic efficacy across PME subtypes including Unverricht-Lundborg disease and Lafora disease, and is discussed as a reasonable option to consider in refractory PME myoclonus generally, with the caveat of psychobehavioral side effects (general PME treatment literature synthesis: Seizure journal review; Neurology India 2024/2026 pragmatic review, PMID 41817056).

• General first-line combination for PME seizure control across the class: valproate + levetiracetam + benzodiazepines, which control seizures but have limited efficacy against the myoclonus itself.

• Advanced therapeutics (gene therapy, cell therapy, RNA-based therapy): None developed or in trials specifically for CERS1/PME8 as of this research (no CERS1-specific gene-therapy program was identified in this search, in contrast to active preclinical/early gene-therapy programs for EPM1/CSTB, per CURE Epilepsy).

• Surgical/interventional: Not applicable/not reported.
• Supportive/rehabilitative care: Implied standard-of-care for progressive movement disorder and cognitive decline (physical therapy, occupational therapy, speech therapy for dysarthria) though not explicitly detailed in the retrieved case reports.
• Experimental treatments/clinical trials: No CERS1/PME8-specific clinical trials were identified on ClinicalTrials.gov searches performed in this session.
• Treatment outcomes: Seizures can be pharmacologically controlled, but myoclonus and cognitive decline continue to progress despite treatment ("controlled seizures but progressive cognitive decline and myoclonus worsening").
• Suggested NCIT terms: NCIT:C15986 (Pharmacotherapy, generic action term) with therapeutic_agent bound to CHEBI terms for valproic acid, topiramate, clonazepam, primidone, levetiracetam, piracetam, and perampanel individually.

13. Prevention

• Primary prevention: Not possible (monogenic disease); the only actionable primary-prevention lever is genetic counseling and reproductive planning for consanguineous families/carrier couples with a known family history — carrier testing, prenatal diagnosis, or preimplantation genetic diagnosis (PGD) could theoretically be offered once a familial pathogenic variant is identified, though this was not explicitly documented as having been performed in the reviewed reports.
• Secondary prevention: Early diagnosis via genetic testing (once PME is suspected clinically) allows earlier initiation of symptomatic antiseizure therapy, though this does not alter the underlying neurodegenerative trajectory.
• Tertiary prevention: Optimized antiseizure regimen to reduce seizure-related morbidity (injury from myoclonic jerks/GTC seizures) and supportive rehabilitative care to maintain function as long as possible.
• Screening/genetic counseling: Recommended for consanguineous families with an affected child — standard 25% recurrence risk counseling for autosomal recessive disease applies once carrier status of both parents is confirmed.
• Public health/behavioral interventions: Not applicable (no described modifiable environmental or lifestyle risk factor).

14. Other Species / Natural Disease

• No naturally occurring CERS1-associated disease has been reported in companion animals or wildlife (no OMIA entry identified in this search).
• Orthologous gene: Mouse Cers1 (also historically Lass1; MGI:2136690), located on a syntenic region; extensively studied as the toppler and flincher spontaneous mouse mutant alleles (see Model Organisms, below).

15. Model Organisms

Primary and best-characterized model: mouse (Mus musculus), Cers1 mutants "toppler" and "flincher."

• Model type: Spontaneous point-mutation mouse alleles in the acyl-chain binding loop of Cers1 (naturally occurring, not engineered knockouts), maintained/distributed via The Jackson Laboratory (strain 019483, "toppler").
• Phenotype recapitulation: Homozygous toppler/flincher mice display reduced body and brain weight, small cerebellum, progressive tremor, ataxia, impaired balance, and seizures, with dramatic dendritic abnormalities and severe loss of cerebellar Purkinje cells, glial changes, and shortened lifespan — closely recapitulating the human PME8 triad of ataxia, seizures, and cerebellar degeneration (Zhao et al., PLoS Genetics 2011, PMID: 21625621).
• Biochemical concordance: Mutant mouse brain homogenates show decreased Cers1 enzymatic activity, decreased C18-ceramide, and ~50% reduction in total brain ceramide — directly mirroring the proposed human disease biochemistry — plus widespread intraneuronal autofluorescent lipofuscin and ubiquitylated protein accumulation, especially in brainstem and cerebellum, paralleling the human MRI finding of brainstem/cerebellar atrophy.
• Fidelity/limitations: High fidelity for the cerebellar/ataxic and seizure components of the phenotype; the toppler/flincher alleles are hypomorphic point mutations (not null), which may better model the human missense-variant genotype than a complete knockout would. Full concordance with the human cognitive-decline/dementia phenotype has not been separately validated behaviorally in the mouse literature retrieved here.
• Distinct paralog model (for contrast, not to be conflated with CERS1): Cers2-null mice show myelin sheath defects, cerebellar degeneration, symmetrical myoclonic jerks, and light sensitivity — modeling the related but genetically distinct CERS2-linked PME, and useful as a comparative/complementary model illustrating shared downstream ceramide-deficiency pathophysiology with tissue/chain-length-specific differences (PMC4212479, synthesized).
• Research applications: The toppler/flincher model has been used to establish the causal link between ceramide biosynthesis deficiency, lipofuscin/ubiquitinated-protein accumulation, and Purkinje neurodegeneration, directly informing the mechanistic model proposed for human PME8, and providing a platform for testing potential ceramide-pathway-targeted interventions (none yet translated to human trials per this search).
• Resources: MGI:2136690 (Cers1); JAX strain 019483.

Summary of Key Evidence Gaps for Curation

1. Exact cytoband (19p13.11 vs 19p13.12) should be verified against NCBI Gene/Ensembl directly rather than relying on the conflicting search-snippet values obtained here.
2. gnomAD allele frequencies for the specific reported pathogenic variants (p.Arg255Cys, p.Pro140Leu, and the original Vanni et al. 2014 index-family variant) were not retrievable in this session and should be looked up directly in gnomAD/ClinVar before curation.
3. The exact missense variant and full clinical description from the original Vanni et al. 2014 Annals of Neurology paper (PMID: 24782409) could not be fetched directly in this session (403/cookie-blocked); only secondary syntheses were obtained. Full-text/abstract retrieval and direct snippet verification against the cached PubMed abstract is required before using any Vanni et al. 2014 quote as curated evidence, per this KB's anti-hallucination SOP.
4. Similarly, OMIM 616230's full clinical synopsis and the Ferlazzo et al. 2016 Epileptic Disorders case report (PMID search returned title/abstract page but fetch was blocked by 403) should be independently re-fetched (e.g., via just fetch-reference) rather than curated from this report's secondary synthesis.
5. Exact country/ancestry of the second reported family (PMC6336183) should be confirmed against the primary source (search synthesis described "mixed indigenous, Portuguese, and Dutch ancestry," suggestive of a Brazilian/South American case, but this was not explicitly stated in retrievable text).

All PMIDs and identifiers above should be independently fetched and snippet-verified (just fetch-reference, just count-verified-snippets) before being entered as evidence items in a dismech disorder YAML file, per this repository's evidence SOP — this report is a research lead, not pre-verified curation content.

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

Every one of these was searched against an abstract alone, with no full text retrieved - marked abstract only below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.

• PMID:21625621 (abstract only): "leads to accumulation of lipofuscin ... associated with ubiquitylated proteins in many regions of the brain, suggesting that ceramide biosynthesis is critical for protein and organelle homeostasis"
• closest text in source: "In addition to Purkinje cell death, deficiency of CerS1 function also induced accumulation of lipofuscin with ubiquitylated proteins in many brain regions"